ABSTRACT Human B cell lymphoma and murine T cell leukemia can be initiated by several agents. The present paper formulates some thoughts on the role of cytogenetic changes in the subsequent neoplastic process. Initiation creates long-lived preneoplastic cells. In some respects, they are comparable to in vitro-transformed ("immortalized") cell lines that maintain a diploid karyotype and are not tumorigenic in vivo. The development of a tumorigenic ("autonomous") clone is dependent on additional changes at the genetic level. In human B and murine T cell Iymphoma, there are characteristic nonrandom chromosomal changes. The 14q+ marker appears to play a key role in human B cell lymphomas. The reciprocal 8;14 translocation in Burkitt lymphoma is a specialized subclass within this category. In murine T cell leukemia, trisomy 15 is the predominant change. The clustering of these nonrandom changes to tumors derived from a certain cell type rather than to tumors induced by a given etiological agent has important implications for the understanding of the genetic control of cellular responsiveness to growth-regulating forces in vivo.
siveness to growth-regulating forces in vivo. The purpose of this paper is to formulate some thoughts generated by recent cytogenetic studies on lymphomas in mice and humans. It appears that lymphoma development can be initiated by a variety of agents. In all probability, the initiation process creates long-lived preneoplastic cells frozen in their state of differentiation and capable of continued division. These cells constitute the raw material for the subsequent cytogenetic evolution that converges towards a common, distinctive pattern. The nature of this pattern, as it appears in the overt lymphoma, depends on the subclass of the target lymphocyte, rather than on the initiating ("etiological") agent. Human lymphomas The most extensive evidence concerns Burkitt lymphoma (BL) . About 97% of the BLs tested that arose in the high endemic regions of Africa were monoclonal proliferations of EpsteinBarr virus (EBV)-carrying cell clones of B lymphocyte origin (1) (2) (3) . BL tumor cells in vtvo and derived cell lines are similar in carrying multiple copies of the EBV genome, often around 30-40 per cell. Some of the EBV genome copies are integrated with the cellular DNA, while the majority are present as free plasmids (4) . BL cells show no detectable viral expression in vivo except the EBV-determined nuclear antigen, EBNA (5), a DNA-binding protein that is present in all EBV DNA-carrying cells. Superficially at least, the properties of EBNA resemble those of the tumor (T) antigens induced by the oncogenic papovaviruses (6) . In the majority of the cases, BL-derived cell lines arise by the growth in vitro of the clone that is tumorigenic in vivo (7, 8) . These cell lines are also similar to the tumor in vivo with regard to EBNA expression. In addition, many lines (termed producers) also contain a small number of cells that switch on viral production; other lines are nonproducers (9) .
EBV-carrying lymphoid cell lines with an essentially similar EBV DNA status and viral gene expression can also be derived from the peripheral blood (10) or the lymph nodes (11) of normal seropositive donors; they are referred to as lymphoblastoid cell lines (LCLs). LCLs differ from BL lines in a number of phenotypic characteristics (12) . On the basis of the limited information now available, it has not been possible to attribute this to differences in the viral genome or the virus-cell relationship (for review see ref. 4) . The cytogenetic differences between LCLs and BL lines, discussed below, suggest, on the other hand, that the differences may be determined by the cellular genome rather than by the viral genome.
There is firm evidence that EBV is a transforming virus in vitro (13-16) and induces fatal lymphoproliferative disease in certain nonhuman primates in vtvo (17) . In humans, primary infection of adolescents or young adults causes infectious mononucleosis, a self-limiting benign lymphoproliferative disease (for review see ref. 18 ). During mononucleosis, a relatively small number of EBV-carrying B blasts appear in the peripheral circulation; they disappear again during convalescence (19) . They are probably reduced in number by the EBV-specific killer T cells that appear in parallel. The killer cells can lyse autologous and allogeneic EBV-carrying (but not EBV-negative) target cells without any apparent syngeneic restriction (20) (21) (22) (23) . The lymphoid tissues of a person with a rare fatal case were infiltrated with EBNA-positive cells (24) . In some acute cases of infectious mononucleosis, EBV DNA could be demonstrated in the bone marrow during the acute phase of the disease (25) . Infectious mononucleosis is thus accompanied by, and probably due to, an extensive but usually temporary proliferation of EBV-carrying cells.
Experimental oncogenicity of EBV, as far as is known, is entirely restricted to a few New World monkey species (17) . Large apes and Old World monkeys are resistant. This is understandable, because they carry EBV-related herpesviruses that induce cross-neutralizing antibodies. The EBV-like chimpanzee, baboon, and orangoutan viruses were studied in some detail (26) (27) (28) (29) (33) . 14q+ markers were subsequently described in a variety of other lymphoreticular neoplasias (31, (34) (35) (36) (37) (38) (39) We have previously suggested (42) that BL develops in at least three steps. In African BL, the first step is the EBV-induced immortalization of some B lymphocytes upon primary infection. This does not differ from the seroconversion of normal EBV carriers, except perhaps in one respect. The prospective study in the high endemic West Nile district has suggested that pre-BL patients may carry a higher load of EBVharboring cells than normal controls (43) . The second step is brought about by an environment-dependent factor, perhaps chronic holoendemic malaria (44, 45) The reciprocal translocation could arise by a purely random Darwinian process or by more specific mechanisms, as suggested by Fukuhara and Rowley (34) . The ubiquity of EBV, the high virus load carried by the African populations at risk, and the large number of cell divisions that must occur in the chronically hyperplastic lymphoreticular system of the parasite-loaded children makes a purely random process perfectly conceivable, particularly when contrasted against the relative rarity of the disease, even in the high endemic regions.
EBV-negative BLs constitute the majority of the sporadic cases in nonendemic areas (46) (50) . Trisomy 17 was the second most common anomaly, much less frequent than trisomy 15 and never found without the latter. Trisomy 15 was also identified as the main cytogenetic change in x-ray-induced mouse lymphomas (51) . In contrast, lymphoreticular neoplasias of non-T cell origin, induced by the Rauscher, Friend, Graffi, and Duplan viruses, some B lymphomas of spontaneous origin, and a series of mineral oil-induced plasmocytomas showed no trisomy 15 (F. Wiener The trisomy of the spontaneous AKR leukemia is particularly remarkable in this context. The high leukemia incidence of this strain stems from prolonged inbreeding and selection for leukemia. AKR mice contain at least four different genetic systems that favor leukemia development by independent mechanisms: the integrated proviral DNA of the leukemogenic Gross virus, the Fv-1 amplification system, the Rgv-l1-determined relative unresponsiveness of the host to the leukemic cells, and an increased tendency of the target T cells for neoplastic transformation (for review see ref. 53 ). In spite of this high and most artificial bias for leukemia, the disease fails to appear until 6-8 months after birth. This long latency period, together with the appearance of trisomy 15 in overt leukemia, supports the notion that the leukemogenic virus is not self-sufficient in changing normal T lymphocytes to autonomous leukemia cells.
Is there a specific region on chromosome 15 that needs to be It is noteworthy that transformed fibroblasts and lymphocytes show certain common changes associated with immortalization in spite of their very different phenotypes-namely, increased resistance to saturation density, decreased serum requirements, and altered lectin agglutination and capping patterns (58) (59) (60) (61) .
Most DNA viruses that transform in vitro induce DNA synthesis and mitosis in their target cells (62) (63) (64) (65) (66) . For the oncogenic papovavirus systems, it has been shown that the virally determined T-antigen, or one form of it, plays a direct role in initiating host cell DNA synthesis (66) . If transformation in vitro reflects a "built-in" ability to grow in the absence of exogenous stimulation, tumorigenicity in vivo must imply resistance to negative feedback regulations of the host, in addition. The latter may be brought out by appropriate cytogenetic changes. Trisomy, as observed in the murine T cell leukemias, may tilt the balance of the long-lived preneoplastic cells towards definite disobedience, through gene dose effects. Reciprocal translocations that give rise to the Philadelphia chromosome and the 8;14 translocation associated with BL may also work through gene dosage-e.g., by position effects that stop the function of important regulatory genes when they are dislocated from their natural surroundings. Similar position effects may be responsible for the action of src, the extra genetic information carried by the transforming avian sarcoma viruses. Conceivably, this originally cell-derived information may become integrated, together with the rest of the proviral DNA, into new regions where it is no longer subject to the same control as in the original location (67, 68 (78, 79) . Concept of convergence in tumor evolution This concept is not new. In essence, it corresponds to one of the rules of tumor progression, as formulated by Foulds (80) . He stated that the "multiple reassortment of unit characteristics" that formed the basis of the progression concept "could follow one of several alternative pathways of development." Some aspects of this process were stated here in a more specific way. They are as follows:
(i) Like chemical or physical carcinogens, viruses play essentially the role of initiators in tumor progression. Their major effect is the establishment of long-lived preneoplastic cells.
(ii) Specific genetic changes are responsible for the transition of preneoplastic to frankly malignant cells. In some systems, they are expressed as cytogenetically detectable chromosomal anomalies, characteristic for the majority of the tumors that originate from the same target cell. The changes may arise by random mechanisms. They are selectively fixed, due to the increased growth advantage of the clone that carries them. This advantage is based on a decreased responsiveness to growthcontrolling or differentiation-inducing host signals. This selection process, rather than any specific induction mechanism, is responsible for the "cytogenetic convergence" of preneoplastic cell lineages, initiated ("caused") by widely'diverse agents, towards the same nonrandom chromosomal change.
(iii) The cytogenetic changes act by shifting the balance between genes that favor progressive growth in vivo and genes that counteract it. Changes in effective gene dosage are brought about by nonrandom duplication of a whole chromosome, as in trisomy, or by reciprocal translocation that may effect gene expression on the donor or the recipient chromosome.
Note Added in Proof. The statement supported by ref. 4 is also supported by refs. 81 and 82.
